Duality Advisers’s BioMarin Pharmaceuticals BMRN Stock Holding History

Duality Advisers’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-12,579	Closed	-$1.3M	–	567
2022 Q4	$1.3M	Sell	12,579 -9,708	-44%	-$911K	0.15%	247
2022 Q3	$1.89M	Buy	22,287 +19,146	+610%	+$1.7M	0.21%	191
2022 Q2	$260K	Sell	3,141 -15,364	-83%	-$1.22M	0.03%	543
2022 Q1	$1.43M	Buy	+18,505	New	+$1.55M	0.15%	246
2021 Q2	–	Sell	-28,895	Closed	-$2.18M	–	545
2021 Q1	$2.18M	Buy	+28,895	New	+$2.36M	0.19%	193

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Duality Advisers's BMRN Position: Q1 2023 in Review

Duality Advisers sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2023, closing a stake of 12,579 shares — an estimated $1.3M sold.

Duality Advisers first reported a position in BMRN in Q1 2021 and held it in 5 quarters. The position peaked at $2.18M in Q1 2021. 552 funds tracked by Wall St. Rank hold BMRN as of Q1 2023.

Duality Advisers reported no remaining BioMarin Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Duality Advisers sold 12,579 BioMarin Pharmaceuticals shares in Q1 2023, an estimated $1.3M.
Duality Advisers first reported a position in BioMarin Pharmaceuticals in Q1 2021 and held it in 5 quarters.
Duality Advisers's BioMarin Pharmaceuticals position peaked at $2.18M in Q1 2021.
552 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2023.

Based on Duality Advisers's 13F filing for Q1 2023, filed 27 Jun 2023.